BioCentury
ARTICLE | Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

September 7, 2018 4:45 PM UTC

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the IPF Summit in San Francisco.

Bridge Biotherapeutics plans to submit an IND to FDA by year end for the small molecule inhibitor of autotaxin (ENPP2; ATX). The company said it believes BBT-877 has the potential to become the best-in-class drug for IPF...